Yüklüyor......
Use of Raloxifene and Tamoxifen by Breast Cancer Risk Level in a Medicare-1 eligible Cohort
BACKGROUND: Raloxifene and tamoxifen are FDA approved for breast cancer risk reduction; in 2013, the US Preventive Services Task Force (USPSTF) recommended these drugs for breast cancer risk reduction in high-risk women. Information on use of raloxifene and tamoxifen for breast cancer risk reduction...
Kaydedildi:
| Yayımlandı: | Am J Obstet Gynecol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5970073/ https://ncbi.nlm.nih.gov/pubmed/29630889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajog.2018.03.031 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|